<DOC>
	<DOCNO>NCT00611533</DOCNO>
	<brief_summary>The purpose study examine efficacy atomoxetine ( ATX ) treatment mild moderate cognitive disturbance frequently experience woman menopause transition . In addition , seek determine , use Brown Attention Deficit Disorder Scale ( BADDS ) , whether degree peri- early post-menopausal woman experience cognitive disturbance overlap impairment executive function characteristic adult attention deficit disorder ( ADHD ) .</brief_summary>
	<brief_title>Placebo Controlled Study Atomoxetine Treatment Mild Moderate Cognitive Difficulties Menopausal Women</brief_title>
	<detailed_description>Decline cognitive function , particular memory , frequent complaint menopausal woman seek clinical intervention . While wealth preclinical evidence demonstrate neuroprotective cognitive enhance role estradiol ( Wise et al. , 1999 ; Jezierski &amp; Sohrabji , 2001 ) , recent publicity Women 's Health Initiative Study make gynecologist menopausal woman concern use estrogen therapy ( ET ) address cognitive complaint well symptom menopause ( WHI Writing Group , 2002 ) . Decades data suggest estrogen enhances cognitive function woman undergo surgical natural menopause ( Sherwin et al. , 1998 ) forget wake result WHI . Further , recent finding naturalistic study suggest use estrogen replacement therapy three year mean age 70 year significantly reduce risk Alzheimer 's Disease ( AD ; Zandi et al. , 2002 ) receive sufficient attention lay press scientific circle allay concern . Most recently , conjugate equine estrogen plus medroxyprogesterone acetate ( PremProÂ® ) use daily associate small increase risk dementia ( Schumaker et al. , 2003 ) . Now clinicians woman become hesitant utilize ET , find proverbial rock hard place study demonstrate efficacy agent treatment mild moderate cognitive difficulty healthy non-demented menopausal woman . Thus , timely crucial investigate pharmacologic strategy aim improve cognitive function population . Interestingly , many cognitive complaint detect menopausal woman include , short-term memory , organization task , sustain focus concentration , regulate emotion , overlap symptom frequently report adult ADHD ( Warga , 1999 ; Brown , 2000 ) . That ATX demonstrate efficacy treatment ADHD provide compelling rationale investigate treatment menopause-related decline memory cognitive function . Thus , first double-blind , placebo-controlled , cross-over clinical trial obtain preliminary data efficacy ATX treatment mild moderate cognitive disturbance menopause age woman . Women early menopause choose study clinical preclinical data suggest long period hypoestrogenism may associate poor response intervention ET . Therefore , believe population may likely respond treatment ATX woman postmenopausal many year .</detailed_description>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Menopausal subject age 45 60 year ; Physically healthy major medical illness ; No history within past 5 year DSMIV psychiatric substance abuse diagnosis structure diagnostic interview ( SCID ) ; Subjects determine either peri postmenopausal ; Subjects must within 5 year last menstrual period ; Subjective report cognitive disturbance least mild moderate severity ; All subject must least average intelligence determine use Wechsler Abbreviated Scale Intelligence ( WASI ) . Clinical evidence dementia and/or sign dementia MiniMental Status Exam ( MMSE score &lt; 22 ) ; History familial dementia ; Use psychotropic medication within previous 6 month ; Use estrogen replacement therapy within previous 6 month ; Current pregnancy ; Signs unstable medical neurological disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Cognition</keyword>
</DOC>